Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. South Africa
  4. Johannesburg Stock Exchange
  5. Aspen Pharmacare Holdings Limited
  6. News
  7. Summary
    APN   ZAE000066692

ASPEN PHARMACARE HOLDINGS LIMITED

(APN)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

South Africa's Aspen in advanced talks over COVID-19 vaccine deal

11/29/2021 | 11:10am EST
Workers at South African pharmaceutical major Aspen Pharmacare facility pass a bottle, in Gqeberha

JOHANNESBURG, Nov 29 (Reuters) - Aspen Pharmacare is in advanced discussions over a potential licensing agreement to package the COVID-19 vaccine in South Africa, it said on Monday.

The South African company did not mention the name of the company with which it was in talks, but in early September it said it was in talks with U.S. pharma giant Johnson & Johnson over a vaccine packaging license.

Aspen currently packages J&J's COVID-19 vaccine at its South African plant under contract, which means it does not have any pricing or distribution power over the product.

The company currently produces 300 million COVID-19 vaccine doses annually under its J&J contract, which are then supplied across Africa. It plans to ramp up capacity to 1.3 billion doses by February 2024, Chief Executive Stephen Saad told Reuters in October.

Aspen has not said how many doses from that 1.3 billion would be produced under license were it to secure such a deal with J&J.

Aspen is in "advanced discussions in relation to the possible conclusion of a licensing agreement to allow it to produce and sell a COVID-19 vaccine in Africa," a company statement said. (Reporting by Promit Mukherjee Editing by David Goodman)


© Reuters 2021
All news about ASPEN PHARMACARE HOLDINGS LIMITED
01/20Dozens of firms to make cheap version of Merck COVID pill for poorer nations
RE
01/18ASPEN PHARMACARE : Business update for the six months ended 31 December 2021 and withdrawa..
PU
2021ASPEN PHARMACARE HOLDINGS LIMITED : Proxy Statments
CO
2021ASPEN PHARMACARE : Report on Annual General Meeting proceedings
PU
2021Africans Will Get Wider Access to Vaccines in New Distribution Deal
AQ
2021Aspen confirms non-binding term sheet on manufacture and sale of an aspen branded covid..
AQ
2021S.Africa's Aspen signs deal paving way for J&J COVID vaccine licence
RE
2021South Africa's rand finds support in weaker dollar, stocks firm
RE
2021African Union calls for Aspen-J&J deal to include substance production
RE
2021Johnson & Johnson Units, Aspen Pharmacare Sign Term Sheet for Manufacturing of COVID-19..
MT
More news
Financials
Sales 2022 40 969 M 2 685 M 2 685 M
Net income 2022 6 580 M 431 M 431 M
Net Debt 2022 13 884 M 910 M 910 M
P/E ratio 2022 14,1x
Yield 2022 1,44%
Capitalization 92 854 M 6 082 M 6 085 M
EV / Sales 2022 2,61x
EV / Sales 2023 2,37x
Nbr of Employees 8 844
Free-Float -
Chart ASPEN PHARMACARE HOLDINGS LIMITED
Duration : Period :
Aspen Pharmacare Holdings Limited Technical Analysis Chart | APN | ZAE000066692 | MarketScreener
Technical analysis trends ASPEN PHARMACARE HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 204,00 ZAR
Average target price 263,00 ZAR
Spread / Average Target 28,9%
EPS Revisions
Managers and Directors
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Sean Matthew Capazorio Group Finance Officer & Executive Director
Kuseni Douglas Dlamini Chairman
Lorraine Angela Hill Group Operating Officer
Babalwa Ngonyama Independent Non-Executive Director